Recent studies have clarified that pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH) has some distinctive clinical aspects from other PAH, such as high prevalence, venous and cardiac involvement, less favourable outcome, helpfulness of detection algorithm, response to immunosuppression, pre-PAH conditions in borderline pulmonary arterial pressure and coexistence of interstitial lung disease. In this review, by focusing on these distinctive aspects, we discuss how to provide an efficacious and safe management of CTD-PAH and garner attention to areas where further evidence is desired.
| INTRODUCTION
Pulmonary hypertension (PH) is an increased blood pressure in pulmonary arteries and affects the right side of the heart, being diagnosed when the blood pressure in the circulation of the lung measured by right heart catheterization (RHC) is 25 mm Hg or greater. PH occurs as a consequence of remodelling and constriction of the pulmonary arteries and arterioles, called pulmonary arterial hypertension (PAH) and classified as group 1 PH; impaired left heart function and subsequent pulmonary vascular congestion, group 2 PH; hypoxia-mediated pulmonary vasoconstriction in the presence of lung diseases, group 3 PH; occlusion of the pulmonary vascular bed caused by thromboembolism, group 4 PH; or unclear multifactorial mechanisms, group 5 PH. 1 Of these 5 forms of PH, PAH is of particular clinical significance because of its high mortality if left untreated and the recent advances in specific therapy including endothelin receptor antagonists (ERA), phosphodiesterase type 5 inhibitors (PDE5i), a soluble guanylate cyclase stimulator, prostacyclin analogues and a prostacyclin receptor agonist. Connective tissue diseases (CTD) are the major cause of PAH, occupying around one-fourth of the total PAH population. 2, 3 PAH associated with CTD (CTD-PAH), compared with idiopathic PAH (IPAH), has some unique clinical characteristics, such as less favourable outcome, venous and cardiac involvement and response to immunosuppression. This review focuses on these CTD-PAH-specific aspects and discusses how to efficiently detect and diagnose PAH in CTD patients and to effectively treat CTD-PAH.
| EPIDEMIOLOGY
Compared with a low prevalence, approximately 15 cases per million, in the general population, PAH is not rarely observed in CTD patients. The prevalence of PAH in systemic sclerosis (SSc) patients has been estimated to be around 10% based on a multicenter cohort and meta-analysis. 4 A nationwide French cohort observed an incidence of PAH among SSc patients of 0.61 cases per 100 patientyears. 5 SSc-PAH comprises about 70% of the total CTD-PAH in the USA and Europe, 2,3 whereas PAH associated with other CTD including systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD) and primary Sj€ ogren's syndrome is more common than SSc-PAH in Asia. 6, 7 The precise prevalence of PAH in patients with those non-SSc CTD remains to be determined due to the lack of large cohort study but is expected to be lower than that in SSc patients. PAH develops much more rarely in patients with polymyositis or dermatomyositis. 8 Autoantibodies, particularly some of the antinuclear antibodies, are also associated with the presence of PAH. Anti-U1RNP antibody has been shown to be an independent predictor of PAH development among SLE patients 9 and was the most prevalent autoantibody, followed by anti-SSA/Ro antibody, detected in a Japanese cohort of CTD-PAH. 6 Recently, a
French registry indicated a high prevalence of anti-SSA/Ro and anti-SSB/La antibodies in SLE patients with PAH compared to those without PAH. 10 In a multicenter cohort, anti-centromere antibody, usually detected in the limited cutaneous subset of SSc, was significantly more prevalent in SSc patients with PAH than those without PAH. 
| Other distinctive involvements
In SLE-PAH patients, pulmonary vasculitis as well as immune complex deposition in the intimal and medial layers of the pulmonary vessels, including IgG, IgM, C3 and C1q, has been described, [19] [20] [21] supporting the role of immunosuppression. Antiphospholipid antibodies have been suggested to be associated with group 4 PH (chronic thromboembolic pulmonary hypertension). 22 
| PROGNOSIS
A number of studies and registries have shown a less favourable outcome of patients with SSc-PAH compared to those with IPAH or non-SSc CTD-PAH, with one-and 3-year survival of around 80% and 50%, respectively, [23] [24] [25] [26] [27] whereas the prognosis of non-SSc CTD-PAH patients is comparable to that of IPAH patients. 24 Screening and early detection of PAH are likely to improve the prognosis of SSc-PAH patients. Recent studies applying an early detection algorithm have demonstrated a better outcome of SSc-PAH patients compared to previous cohorts, with 1-and 3-year survival of about 95% and 75%, respectively. [28] [29] [30] Several factors have been identified to portend an increased mortality in CTD-PAH patients, including the elderly, male gender, high World Health Organization (WHO) functional class (FC) at the time of PAH diagnosis, low 6-minute walk distance (6MWD), the presence of pericardial effusion, severely reduced diffusing capacity for carbon monoxide (DL CO ), increased NT-proBNP levels and severe hemodynamic impairment. [27] [28] [29] [30] [31] Interestingly, anti-U1RNP
antibody has been suggested to be a factor protecting against mortality in SSc-PAH, 32 but associated with a lower survival rate in SLE-PAH. 33 
| DETECTION
Given the relatively high prevalence of PAH in patients with CTD, particularly with SSc, and successful screening of PAH in SSc patients to improve their prognosis, the early detection of PAH would be a key process in the management of CTD-PAH. Currently available are consensusbased, evidence-driven recommendations for screening and early detection of CTD-PAH. 34 Patients with SSc and those who have scleroderma spectrum disorders, such as sclerodactyly, nail fold capillary abnormalities or sclerodermaspecific autoantibodies, are recommended to annually undergo screening of PAH, including pulmonary function tests (PFT) with DL CO , transthoracic echocardiogram (TTE) and measurement of NT-proBNP, and to be referred for RHC if positive results are obtained. Conversely, other CTD patients should be screened in a similar manner only when unexplained signs and symptoms of PH develop. The DETECT algorithm 35 is also recommended for screening and early detection of PAH. It is an evidence-based screening algorithm for PAH in SSc patients by calculating risk score for RHC referral from 8 variables including PFT with DL CO , telangiectasias, anti-centromere antibody, NTproBNP, serum urate, right axis deviation on electrocardiogram, right atrium area (measured at TTE) and tricuspid regurgitation velocity (measured at TTE). The PAH risk calculator is available on the website (http://detect-pah.c om). Although there is a lack of evidence regarding the frequency and duration of such screening, at least PFT and TTE are recommended to be performed every year, even in the absence of signs and symptoms of PH, in patients with SSc and those who have scleroderma spectrum disorders. 34 Decreased DL CO and increased NT-proBNP have been shown to be associated with PAH in SSc patients. 36, 37 As DL CO is influenced by lung volumes, forced vital capacity (FVC)/DL CO or DL CO /alveolar volume ratio rather than DL CO itself has been postulated to be a refined PFT parameter to indicate the presence of PAH. It has also been shown that DL CO is decreased in patients with PVOD. 13, 38 RHC triage in CTD patients based on TTE and PFT findings and NT-proBNP levels are summarized in Figure 1 . Representative imaging findings are presented in Figure 2 .
| TREATMENT
The treatment algorithm for CTD-PAH is similar to that for IPAH because CTD patients have constituted at least 20% of the total subjects in major randomized control trials on PAH-specific vasodilators, including both monotherapy and combination therapy. For example, the ERA bosentan showed clinical effectiveness and tolerability for both IPAH and CTD-PAH in a double-blind, placebo-controlled study comprising 213 PAH patients, of which 63 had CTD-PAH, 39 and the PDE5i sildenafil also showed a favourable therapeutic effect in another trial on 278 PAH patients, of which 84 had CTD-PAH. 40 44 demonstrated the superiority of initial upfront combination therapy with the ERA ambrisentan and the PDE5i tadalafil in terms of lowering the risk of clinical failure events in PAH patients compared to ambrisentan or tadalafil monotherapy. In a post hoc analysis from the AMBITION trial, SSc-and other CTD-PAH patients have also been shown to benefit from the initial upfront combination therapy, although the eligibility criteria were amended to require more rigorous haemodynamic measurements to exclude patients in whom other forms of PH than PAH were expected to coexist. 45 Given the less favourable outcome compared to IPAH or non-SSc CTD-PAH patients, SSc-PAH patients may need a more aggressive treatment regimen to see similar benefits to other PAH patients. Conversely, aggressive vasodilation is sometimes associated with a negative effect against other forms of PH, represented by the development of severe pulmonary oedema in patients with PVOD and the worsening of hypoxia in patients with group 3 PH (PH due to lung diseases) likely due to increased ventilation-perfusion mismatch from removal of hypoxiamediated vasoconstriction. PAH-specific vasodilators have also failed to demonstrate obvious clinical benefits for group 2 PH. 46 Therefore, further studies are needed to position initial upfront combination therapy in CTD-PAH, particularly in SSc-PAH which is frequently associated with venous, cardiac and/or interstitial lung involvement. Calcium channel blockers may not be recommended as a vasodilator therapy for CTD-PAH since acute vasoreactivity during haemodynamic testing is <1% in SSc-PAH patients. 47 Anticoagulation in CTD-PAH remains controversial because there have been conflicting results on a survival benefit. [52] [53] [54] [55] [56] [57] [58] However, there is currently no answer on a case of overlap syndrome, such as patients who have both SSc and SLE. Addition of immunosuppression to PAHspecific vasodilator therapy may produce a further therapeutic effect in SLE-PAH patients. 57 Of note, vasodilator resistant case may also respond to immunosuppression. 59 However, the optimal regimen of immunosuppressive therapy remains to be established. In previous studies, the dose of glucocorticoids was equivalent to 0.5-1.0 mg/kg/d of prednisolone, followed by gradual tapering, and IVCY was given monthly, 500-1000 mg per pulse, for 3-12 months in most cases [53] [54] [55] [56] [57] [58] (Table 2 ). Responders to immunosuppressive therapy tended to concomitantly receive vasodilators ( Table 2 ). The favourable effect of mycophenolate mofetil combined with tacrolimus or cyclosporine, rituximab and tocilizumab for CTD-PAH has been reported in a few case reports. 58, [60] [61] [62] [63] Azathioprine might be considered as a maintenance therapy following IVCY. 
INTERSTITIAL LUNG DISEASE
Interstitial lung disease (ILD) is frequently detected by highresolution computed tomography of the chest in patients with CTD-PAH, particularly with SSc-PAH, there was, however, no consensus on the definition of moderate-to-severe ILD to classify a patient in group 3 PH. In most of the clinical trials on PAH, patients with ILD and total lung capacity of <60% were excluded and classified in group 3 PH or "group 3 dominant" PH. 44 Conversely, patients with ILD and mPAP of >40 mm Hg are generally thought to have group 1 dominant PH, so called out of proportion, as only mild elevation of PAP occurs in "pure group 3" PH. In SSc, given the less elevation of PAP as discussed in the previous section, differentiating PAH and group 3 PH is rather more complex. The proportion of group 3 PH therefore needs to be evaluated individually in SSc patients, particularly in those with mPAP of 25-40 mm Hg. Two representative cases of SSc in the presence of both PH and ILD are presented in Figure 2 , in whom PAP was equally elevated (mPAP = 29 mm Hg in both cases), whereas the severity of ILD differed with FVC of 54.8% (Figure 2C) and of 101.0% ( Figure 2D ), compatible with group 3 and group 1 dominant PH, respectively. A recent study by Michelfelder et al 67 compared 27 SSc-PAH patients with 24
SSc-PAH patients coexisting ILD with mean FVC of 60 (AE14) % and found a lower survival rate in SSc-PAH-ILD patients but did not find a difference in haemodynamic measurements, NT-proBNP levels, FVC/DL CO ratio, 6MWD, WHO FC, presence of pericardial effusion and sclerodermaspecific autoantibody levels. The impact of ILD, even with FVC of >60%, on the mortality of SSc-PAH patients was shown in another cohort study. 51 Given the high-mortality rate and the possible unwanted effect of aggressive vasodilation through an increase of ventilation-perfusion mismatch, the treatment regimen for SSc-PAH coexisting ILD, particularly moderate-to-severe ILD, may differ from that for other PAH but needs further studies to be established.
| CONCLUSION
As discussed above, recent studies have clarified that CTD-PAH has several distinctive aspects from other PAH, including venous and cardiac involvement, helpfulness of detection algorithm, response to immunosuppression, pre-PAH conditions in BoPAP and coexistence of ILD. Owing to the PAH general and CTD-PAH-specific evidence, the prognosis of CTD-PAH patients has been improving. However, there still remain important issues to be solved, such as discrimination of the case coexisting group 1', group 2 and/or group 3 PH, the optimal regimen of immunosuppressive therapy, and the management of BoPAP case. Understanding of the distinctive aspects and current unmet needs may help clinicians to provide an efficacious and safe management of CTD-PAH.
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